Phase 1 Alzheimer's Disease Trial, Not Yet Recruiting NCT07142278 Sponsor: Nuravax, Inc. Condition: Alzheimer's Disease
Back to Alzheimers Disease

Phase 1 Alzheimer's Disease Trial, Not Yet Recruiting

NCT07142278
Not Yet Recruiting Phase 1

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Men and women (who are not pregnant or breastfeeding) between 40 and 65 years old who are generally in good health
  • People with a body mass index (a measure of body weight relative to height) between 18.0 and 32.0
  • People with no significant health problems found during a medical check-up, blood tests, heart tracing (ECG), or brain scan (MRI)
  • People who have read and signed a form agreeing to take part in the study
  • Women who could become pregnant must have a negative pregnancy test and must use reliable contraception during the study
  • Men must either have had a vasectomy or must agree to use condoms and not donate sperm during the study period

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People with a significant physical or mental health condition that could affect their safety or the study results
  • People who have abnormalities on a brain scan (MRI), such as signs of stroke or small bleeds, or who are unable to have an MRI for any reason
  • People with significant abnormalities in blood test results (such as liver, kidney, or blood cell problems) or who test positive for HIV, hepatitis B, or hepatitis C
  • People with uncontrolled high blood pressure, an abnormal heart rate, or a specific abnormality in the heart's electrical activity (confirm with trial site)
  • People who have had a serious illness, surgery, or taken part in another drug study within the last 30 days
  • People who have received a treatment targeting amyloid-beta or tau proteins (related to dementia research) within the past year
  • People currently taking medicines that suppress the immune system or long-term blood-thinning medications
  • People with a history of severe reactions to vaccines, autoimmune disease, or serious allergies

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 10 August 2026

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 1
Sponsor
Nuravax, Inc.
Registry
ClinicalTrials.gov
Start date
1 November 2025
Est. completion
1 April 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Participants with Treatment-Emergent Adverse Events (TEAEs), including Adverse Events of Special Interest (AESI)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 10 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov